广生堂(300436.SZ)子公司广生中霖参与新发突发与重大传染病防控国家科技重大专项

Core Viewpoint - Guangshentang's subsidiary, Fujian Guangshen Zhonglin Biotechnology Co., Ltd., has received approval for its participation in a national major science and technology project focused on the clinical cure of chronic hepatitis B [1] Group 1 - The project is titled "Research on New Combined Treatment Plans for the Clinical Cure of Chronic Hepatitis B" and is part of a national initiative for the prevention and control of emerging infectious diseases [1] - Guangshen Zhonglin is responsible for research work on specific topics within the project, namely Topic 1 and Topic 3 [1] - The innovative drugs GST-HG131 and GST-HG141, along with combination therapies, will be used as research medications in the project [1]